Biologics are the future of innovative therapeutics in dermatology. Various biologics such as monoclonal antibodies, recombinant human cytokines, and growth factors, are used for dermatology treatment.
Conventional plaque psoriasis treatment often fails to give significant results, and also produces side effects such as mouth sores, nausea, stomach upsets, and in rare cases, skin cancer. On the other hand, biologics are more target-specific compared to conventional therapies, as biologics only target psoriasis-causing proteins of the immune system, thus leading to better outcomes and fewer side effects.
Leading players in biopharmaceuticals such as Abbvie, Novartis, Eli Lilly, and Johnson & Johnson are focusing on developing/manufacturing biologics for plaque psoriasis.
In the U.S., there are around ten pipeline biological molecules targeting plaque psoriasis, out of which two are new biological entity (NBE) and two are biosimilars. This pipeline trend seems to indicate potential for biologics in plaque psoriasis management.
For more in-depth data and key insights on monoclonal antibodies in dermatology such as pharmacological targets, addressable patient population, order of entry by drug class, methods of administration etc., we invite you to have demo trial of Phase-XS platform which supports your business decisions by providing clinical, market, and competition insights.
Enquire about Phase-XS (Bio-pharmaceutical database) @ https://www.coherentmarketinsights.com/phasexs-enquiry
Coherent Market Insights, through its PHASE-XS offering, intends to help companies already investing, or willing to invest in biologics and biosimilars, get a futuristic market purview to help gauge their investment values and expected returns. Key insights offered by PHASE-XS include:
- New Biological Entity/Biological license application
- Technology of biologics/biosimilars
- New indications for approved biologics
- Most active companies in the market
- Number of approved drugs in respective drug class
- Major competitor drugs
- Method of administration
- Market potential
- Market size
- Identify white spaces
- Identify products with significant revenue opportunity
By 2020, biologics are expected to account for a quarter of the pharmaceutical market. Therefore, it is essential to gain better understanding of this segment and its competition.
Get more details about Phase-XS (Biologics and Biosimilars Market Tool) @ https://www.coherentmarketinsights.com/phasexs/
Contact Us:
Mr. Shah
Coherent Market Insights
1001 4th Ave.
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com
